INDEMNIFICATION AGREEMENTIndemnification Agreement • September 9th, 2021 • Cingulate Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of ____________, 2021 by and between Cingulate Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 9th, 2021 • Cingulate Inc. • Pharmaceutical preparations • New Jersey
This AGREEMENT (this “Agreement”) is made and effective as of this 1st day of January, 2021 by and between CINGULATE INC., a Delaware corporation, whose principal address is 1901 W. 47th Place, 3rd Floor, Kansas City, KS 66205 (the “Company”) and RAUL R. SILVA, whose address is [**] (the “Employee”). (The Company and the Employee hereinafter sometimes referred to as the “Parties”.)
PATENT AND KNOW-HOW LICENCE AGREEMENT between BDD PHARMA LIMITED and CINGULATE THERAPEUTICS LLC and, solely for the purposes of Clause 12.3 DRUG DELIVERY INTERNATIONAL LIMITEDLicence Agreement • September 9th, 2021 • Cingulate Inc. • Pharmaceutical preparations • London
Mr. Edward Dresch Dresch Inc. Dear Mr. Dresch,Cingulate Inc. • September 9th, 2021 • Pharmaceutical preparations
The undersigned parties to Promissory Note dated January 27, 2020 (the “Note”), by and between Edward Dresch (“Lender”), and Cingulate Therapeutics LLC (“Borrower”), for a total principle of $500,000.00 hereby mutually agree to amend said Note to change the Paid in Full dated to “February 1, 2022”. All other items of the Contract shall remain in full force and effect.
AGREEMENT AND PLAN OF MERGER BY AND AMONG CINGULATE THERAPEUTICS LLC CINGULATE INC. AND CINGULATE PHARMA LLC DATED AS OF AUGUST 30, 2021Agreement and Plan of Merger • September 9th, 2021 • Cingulate Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of August 30, 2021 by and among Cingulate Therapeutics LLC, a Delaware limited liability company (“CTx”), Cingulate Inc., a Delaware corporation and wholly-owned subsidiary of CTx (“Parent”), and Cingulate Pharma LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Merger Sub”).
April 19, 2021Cingulate Inc. • September 9th, 2021 • Pharmaceutical preparations
The undersigned parties to Promissory Note dated July 25, 2020 (the “Note”), by and between Raul Silva (“Lender”), and Cingulate Therapeutics LLC (“Borrower”), for a total principle of $100,000.00, hereby mutually agree to amend said Note to change the Paid in Full date to “February 24, 2022”. All other terms of the Contract shall remain in full force and effect.
April 28, 2021Cingulate Inc. • September 9th, 2021 • Pharmaceutical preparations
The undersigned parties to Promissory Notes dated February 26, 2020 and September 30, 2020 (jointly, the “Notes”), by and between Matthew Brams (“Lender”), and Cingulate Therapeutics LLC (“Borrower”), for a total principle of $354,000.00 (previously, and partially repaid by the Borrower), hereby mutually agree to amend said Notes to change both Paid in Full dates to “February 24, 2022”. All other terms of the Contract shall remain in full force and effect.
MASTER SERVICES AGREEMENTMaster Services Agreement • September 9th, 2021 • Cingulate Inc. • Pharmaceutical preparations • Pennsylvania
This Master Services Agreement (“Agreement”), effective as of the last signature date of this agreement (the “Effective Date”), is by and between Pharmaceutical Manufacturing Research Services, Inc., having its principal place of business at 202 Precision Road, Horsham, PA 19044 (“PMRS”) and Cingulate Therapeutics, LLC having its principal place of business at 1901 W. 47th Place, Kansas City, KS 66205 (“CTx”).
